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1 |  INTRODUCTION
Calcific uremic arteriolopathy (CUA), or calciphylaxis, is 
an inflammatory condition in which calcium deposits on 
arteriolar vascular beds, leading to ischemia, cell damage, 
and sometimes necrosis. Sodium thiosulfate (STS) has 
emerged as a first- line treatment for CUA ulcers and ne-
crosis, but much remains unknown about its metabolism 
and toxicity. We present a case in which a patient devel-
oped severe metabolic acidosis with an anion gap follow-
ing STS infusion, which was distinctly out of proportion 
with the expected metabolic changes. Hydrogen sulfide is a 
known metabolite of STS, and its role in hypoxia signaling 
in vascular beds and its neutralization of reactive oxygen 
species may contribute to the therapeutic role of STS. In 
chronic kidney disease (CKD), levels of hydrogen sulfide 
are reduced and restoring endogenous levels may be an 
important mechanism of STS action. The toxicity profile 
of hydrogen sulfide includes inhibition of mitochondrial 
ATP production and extreme lactic acidosis, possible con-
tributor to the metabolic acidosis with an anion gap. Still, 
given the rarity of this reaction, some patients may possess 
a metabolic phenotype that confers a predisposition to this 
dangerous event.
Calcific uremic arteriolopathy is an inflammatory condi-
tion associated with end- stage renal disease (ESRD) in which 
calcium salts deposit on arteriolar vascular beds, leading to 
ischemia, cell damage, and possibly necrosis.1 CUA is pos-
itively associated with female sex, obesity, diabetes, protein 
C deficiency, hyperphosphatemia, hypercalcemia, the use of 
calcium- based phosphate binders, and warfarin use in pa-
tients requiring renal replacement therapy, but more cases are 
being seen with normal calcium and phosphate levels due to 
better standards of care.1 The incidence of CUA in ESRD 
has been documented for 5.7 cases per 10 000 chronic he-
modialysis patients in 2011 and is rising2; prevalence as high 
as 4% has been documented 3 with variability attributed to 
differences to the years of the studies published and changing 
identification of the disease and management of risk factors 
contributing to CUA development. This is a serious condi-
tion, which can cause life- threatening infections or organ 
failure when left untreated. Historically, CUA is associated 
with an overall poor prognosis and a mortality rate per year 
ranging between 64% and 80%. The mortality rate has likely 
decreased in the past decade due to treatment with sodium 
thiosulfate (STS), which has been adopted as standard of care 
without evidence derived from large trials.1 STS is regarded 
by many to be a benign treatment, with nausea, vomiting, and 
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Key Clinical Message
Sodium thiosulfate (STS), first- line treatment for calcific uremic arteriolopathy, 
causes a mild asymptomatic acidosis in many patients. However, severe, life- 
threatening acidosis out of proportion with the expected acid load of STS may occur, 
potentially due to metabolism of STS to hydrogen sulfide.
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abdominal pain as the most frequent side effects.1 There is 
emerging evidence that a minority of patients may unpredict-
ably experience metabolic acidosis with a very high anion 
gap, resulting in delirium, weakness, or cardiac arrhythmia.4 
Here, we describe a metabolic acidosis that developed after 
STS infusion and review the literature to provide a potential 
explanation.
2 |  CASE REPORT
A 68- year- old Caucasian woman with end- stage renal dis-
ease on dialysis was admitted to our facility for a stroke 
and a non- ST segment elevation myocardial infarction. The 
stroke caused a right facial droop and right upper extrem-
ity flaccid paralysis, without any other sensory or cognitive 
disturbances. Her chronic medical conditions included type 
2 diabetes mellitus (20- year history, hemoglobin A1C 6.6% 
on admission), atherosclerotic coronary vascular disease, 
ischemic cardiomyopathy with an ejection fraction of 35%, 
congestive heart failure, paroxysmal atrial fibrillation on 
warfarin anticoagulation, hypertension, and hyperlipidemia. 
She had been receiving dialysis for 2 months and was anuric. 
Concurrently, she was found to have tender, nonhealing, ne-
crotic, violaceous, ulcerating plaques of her right shin and 
left posterior calf, which were evaluated by dermatology and 
thought to be consistent with CUA. Biopsies were not ob-
tained due to supratherapeutic INR and concern for inability 
to heal from biopsy. Antibiotics (clindamycin, later changed 
to vancomycin) were initiated. Blood pressure and rate con-
trol therapies with beta- blockers were initiated to mitigate 
myocardial demand ischemia. She was beyond the time range 
for thrombolytic therapy, but her neurologic symptoms did 
not progress under observation.
The patient continued her scheduled intermittent hemodi-
alysis (dialysate of 4 mEq/L potassium, 2.5 mEq/L calcium, 
and 35 mEq/L bicarb, duration of therapy 4 hours, ultrafil-
tration 3 kg) on the day of her admission after medical sta-
bilization. During the last hour of the dialysis session that 
evening, 25 g of STS was also administered intravenously 
to treat her CUA ulcers. The morning following, the patient 
was found to have delirium, hypotension, and a metabolic ac-
idosis with an elevated anion gap (Table 1). ABG revealed 
a primary metabolic acidosis with an increased anion gap, 
mixed with metabolic alkalosis with full respiratory com-
pensation. Lactate and β- hydroxybutyrate were not elevated. 
T A B L E  1  Relevant laboratory values during admission
Admission 
(Hospital Day 0)
Post- STS infusion 
(Hospital Day 1) Hospital Day 2 Hospital Day 3
After Stabilization 
(Hospital Day 4)
pH Arterial 7.35 7.33 Not tested
pCO2 Arterial 41 31 Not tested
Lactate (mmol/L) 2.6 2.7 Not tested
Sodium (mEq/L) 134 139 135
Potassium (mEq/L) 4.7 4.8 4.5
Chloride (mEq/L) 91 88 90
HCO3 (mEq/L) 20 14 21
Anion Gap 23 38 20
Corrected Anion Gap 24.5 39.75 N/A
Blood Urea Nitrogen 
(mg/dL)
58 30 45
Creatinine (mg/dL) 5.41 3.98 3.20
Calcium (mg/dL) 9.1 9.7 7.2
Phosphorus (mg/dL) 3.9 5.5 5.0
β- Hydroxybutyrate 
(mmol/L)
NA 2.31 1.84
Alkaline Phosphatase 
(mg/dL)
105 92 Not tested
Aspartate Transaminase 
(U/L)
41 33 Not tested
Alanine Transaminase 
(U/L)
13 12 Not tested
Albumin (gm/dL) 3.4 2.9 Not tested
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Sepsis was suspected; however, three sets of blood cultures 
were obtained and revealed no growth, and helical computed 
tomography scan of chest, abdomen, and pelvis revealed no 
nidus of infection. Her metabolic acidosis with anion gap did 
not resolve despite daily dialysis with dialysate of 35 mEq/L 
bicarb and stabilized with a supplemental bicarbonate drip; 
her anion gap trended downward over the next 4 days and 
eventually returned to her baseline.
After investigations for potential sepsis, ketosis, lactic ac-
idosis, and uremia, STS was considered to be the probable 
instigating drug in her metabolic derangement. Due to the 
life- threatening nature of this profound anion gap academia, 
the clinical team discontinued STS. She was treated conser-
vatively with the help of our wound care team.
Without STS therapy, her ulcers continued to worsen. She 
was judged to not be a candidate for surgical debridement 
due to her multiple comorbidities. Her hospital stay was com-
plicated by poor nutrition, health care- associated pneumonia, 
and a Clostridium difficile infection. Thirty days into her 
hospital stay, she elected to switch to hospice care and died 
shortly thereafter.
3 |  DISCUSSION
Since its first described use in 2004 for CUA, STS been used 
more frequently, becoming the first- line choice of treatment 
for this condition, which has been known in the community 
for its high morbidity.1,5 Still, despite its longtime use in the 
medical and industrial domains, we understand relatively 
little about its pharmacodynamic effects in the body. In the 
literature, two types of acidosis produced by STS administra-
tion are described: one, a dose- dependent, mild and asympto-
matic acidosis present in most patients on STS therapy6 and 
another, a severe, life- threatening acidosis out of proportion 
with the expected acid load of STS.4 Here, we discuss the 
known pharmacology of STS and discuss the properties of 
hydrogen sulfide, a metabolite of STS, that may play an ad-
ditional role in both STS efficacy and side effects.7
In healthy patients, STS is excreted renally and hepatically 
in equal proportions.8 Previously, a component of biliary ex-
cretion based on canine models was reported, but that does 
not seem to be present in humans.9 A half- life of 3 hours 
or more in healthy subjects has been cited previously,9 but 
newer investigations do not support this figure. 8 Total body 
clearance of STS occurs at a rate of 4.1 and 2.04 mL/min/
kg in healthy subjects and chronic hemodialysis subjects, 
respectively.8 Based on these estimates, the higher plasma 
concentrations needed for optimal calcium chelation are sus-
tained for about 25 minutes in subjects with ESRD, when 
STS is given after dialysis.8 The fast rate of plasma clearance 
implies that the effect of STS on chelating vascular calcifica-
tion is perhaps less important than initially thought or that the 
by- products of its metabolism are more therapeutically active 
than STS itself.
Supporting the role of metabolic by- products are some in 
vitro studies with mouse models that explore the dynamics of 
calcium homeostasis in adipocytes and vascular smooth mus-
cle cells.10 In high- phosphate environments, as is seen with 
ESRD, adipocytes can start to express similar gene profiles 
to osteoclasts, leading to a phenotype change leading to cel-
lular calcification.10 Further, adipocytes induce calcification 
of nearby vascular beds through upregulated VEG- A. This 
effect in a high- phosphorus environment can be dampened 
by the administration of STS, leading to a reduction in adipo-
cyte phenotype changes and nearby vascular calcification for 
at least 3 days.10 This effect contrasts the found half- life of 
STS itself, suggesting that a metabolite impacts transcription 
 factor expression to mitigate calcification in the tissues.
In addition to formation of calcium thiosulfate via che-
lation and its effects on paracrine signaling, STS is thought 
to restore endothelial homeostasis by increasing nitric oxide 
synthase activity and regenerating glutathione.1 This multi-
factorial activity is perhaps responsible for the rapid response 
in pain control some patients experience, as their ability to 
vasodilate is restored before calcium homeostasis.11 The 
exact biochemical pathways of the reactions facilitated by 
STS remain uncharacterized, but they may be in part through 
the action of hydrogen sulfide, whose effects on glutathione, 
nitric oxide, and vasodilation pathways are already known.7 
Endogenous thiosulfate has been hypothesized to act as a 
precursor for hydrogen sulfide to maintain homeostasis, and 
multiple enzymes in multiple tissue types facilitate the reac-
tion from thiosulfate to hydrogen sulfide,12,13 but the exact re-
action under physiologic conditions remains uncharacterized.
Hydrogen sulfide is a key messenger in various pathways 
that coordinate the hypoxic vasodilation/vasoconstriction of vas-
cular beds.7 It also can induce angiogenesis and independently 
protect cells from ischemia.7 In ESRD, endogenous levels of hy-
drogen sulfide are reduced, possibly affected by reactive oxygen 
species or uremia,14 but restoring hydrogen sulfide balance does 
not seem to be an active focus of patient care in ESRD.
In the case of severe, unexpected, and disproportionate met-
abolic acidosis, perhaps hydrogen sulfide can also be impli-
cated. The toxicity of hydrogen sulfide was first discovered in 
accidental exposures of sewer workers to pockets of gas. With 
exposure, patients may experience mucosal irritation, pulmo-
nary edema, loss of consciousness, and sometimes death.15 
Mucosal irritation and pulmonary edema are seemingly re-
lated to direct gas exposures, and loss of consciousness and 
death are the results of excess sulfide in the blood.15 Excess 
hydrogen sulfide can inhibit oxidative phosphorylation, caus-
ing a shortage of ATP, ischemia, and profound lactic acidosis, 
an effect that can be quickly fatal when inhaled in high con-
centrations especially when combined with hypoxia.7,16 When 
dissolved in the tissues in high concentrations, it inhibits the 
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mitochondrial cytochrome complex IV in addition to directly 
causing profound sulfide- generated oxidative stress. 16 This ef-
fect contrasts its ability to reduce oxidative stress in lower con-
centrations by downregulating pro- ROS forming enzymes.7 
While many people can receive 25 g of STS safely, perhaps 
there is a patient- specific idiosyncratic reaction, such as a met-
abolic phenotype or a drug interaction, that we have not yet 
characterized. Further investigation into the pharmacokinetics 
of hydrogen sulfide and its behavior in ESRD is needed.
When thinking about our patient and the others with danger-
ous acidemia, it is still unknown why these events occur. With 
our current understanding of thiosulfate, hydrogen sulfide, and 
the physiology of ischemia, there are several possibilities: (1) 
the acid formed from thiosulfate becoming thiosulfuric acid in 
an aqueous solution during administration; (2) the direct hy-
drogen load of hydrogen sulfide; (3) lactic acid accumulation 
from ATP production inhibition; (4) an insurmountable oxida-
tive stress from sulfide- containing compounds; and (5) a rare 
phenotype that makes the above more likely to occur.
4 |  CONCLUSION
As STS use in ESRD populations increases, we are begin-
ning to characterize side effects of STS, which include a mild 
acidosis from the administration of an acidic compound and a 
distinctly different and more extreme acidosis with an anion 
gap out of proportion with the acid load of the drug itself. We 
do not know why this reaction occurs in some patients or what 
the predisposing factors may be, but metabolites of STS may 
be responsible. Hydrogen sulfide is a ubiquitous inorganic 
compound in the body and has known effects on vascular in-
flammation and oxygen delivery. While still unexplored, the 
breakdown of thiosulfate to hydrogen sulfide may be responsi-
ble for the drug’s efficacy. Similarly, the toxicity profile of hy-
drogen sulfide, as seen in accidental occupational exposures, 
may provide some clues as to why some patients develop pro-
found metabolic acidosis. More research is needed into finding 
the cause of such a dangerous idiosyncratic reaction.
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